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Summary Contrast-induced nephropathy (CIN) has been increasing and seems to be associ-
ated with clinical outcomes in ischemic heart disease. This study aimed to assess the incidence,
predictors, and cardiac outcomes of CIN when nonionic isosmolar contrast media (iodixanol,
Visipaque®, GE Healthcare, Cork, Ireland) was used. Between January 2005 and July 2008, 510
patients (69.2± 9.0 years of age, 384 men) undergoing diagnostic coronary angiography (CAG) or
percutaneous coronary intervention (PCI) were divided into two groups according to the devel-
opment of CIN (CIN group: n = 74; non-CIN group: n = 436). CIN developed in 74 patients (14.5%).
They were more likely to have diabetes (55.4% vs. 42.9%, p = 0.045), decreased left ventricular
ejection fraction (LVEF) (50.1± 12.6% vs. 57.7± 13.9%, p < 0.001), and lower baseline hemat-
ocrit level (32.4± 5.3% vs. 36.6± 5.5%, p < 0.001). Multiple logistic regression analysis revealed
baseline hematocrit (odds ratio 0.900, 95% conﬁdence interval 0.851—0.952, p < 0.001),
decreased LVEF (odds ratio 0.967, 95% conﬁdence interval 0.949—0.986, p = 0.001), and baseline
creatinine level (odds ratio 2.317, 95% conﬁdence interval 1.252—4.286, p = 0.007) as indepen-
dent predictors of CIN. At 1-year follow-up, patients with CIN were found to have more adverse
outcomes than without CIN in Cox proportional hazards analysis (hazard ratio 13.068, 95% con-
ﬁdence interval 2.425—70.434,
level rather than CM amount usi
worse event-free survival than p
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Introduction
Contrast-induced nephropathy (CIN) has been generally
characterized by an increase in serum creatinine (Cr) con-
centration of at least 0.5mg/dL or by a relative increase
of at least 25% from baseline after use of contrast media
(CM) [1]. To date, various predictive factors for CIN have
been reported. They are grouped into two major categories:
patient related and non-patient related factors. The former
refers to chronic kidney disease, diabetes mellitus, urgent
procedure, intra-aortic balloon pump, congestive heart fail-
ure, age, hypertension, low hematocrit, hypotension, and
low left ventricular ejection fraction, and the latter consists
of high osmolar CM, ionic CM, contrast viscosity, and con-
trast volume [2]. Since it was repeatedly reported that CIN
is associated with prolonged hospitalization and increased
morbidity and mortality [3—7], minimizing risk factors for
CIN should be done. It can be achieved initially by avoiding
high osmolar or ionic CM, the easily modiﬁable risk factor.
Contrary to general expectations, there were a few
studies about using nonionic isosmolar CM. A former study
suggested that isosmolar, nonionic CM may be superior
to others in a randomized controlled trial [8]. However,
several subsequent studies failed to conﬁrm this. Even a
large-scale study strongly suggested that an isosmolar CM
more often causes clinically relevant renal failure than
a low-osmolar contrast agent [9]. Moreover, various clini-
cal settings according to certain prophylaxis or underlying
diseases have resulted in different outcomes from those
derived from conventional risk factors [10]. The type of CM
could not be the exception. Hence, we should be aware of
the speciﬁc risk factors for CIN from isosmolar CM use and
accordingly, reduce the risk of CIN. The present study was
aimed to investigate the incidence, predictors, and long-
term cardiac outcomes of CIN with use of nonionic isosmolar
CM.
Materials and methods
Study design and sample
Between January 2005 and July 2008, 510 patients
(69.2± 9.0 years of age, 384 men) undergoing diagnostic
coronary angiography or percutaneous coronary intervention
at Heart Center of Chonnam National University Hospital,
Gwangju, South Korea were analyzed retrospectively.
Patients were divided into two groups according to the
development of CIN (CIN group: n = 74; non-CIN group:
n = 436). Of the 510 subjects, 487 were followed up for 1-
year and we analyzed long-term clinical outcomes in those
patients.
Deﬁnitions
CIN was deﬁned as an increase of ≥25% or ≥0.5mg/dL
in pre-procedure serum Cr after procedure. Cr level was
measured at baseline and daily for 3 days after the
procedure for most of the patients. Two daily measure-
ments of Cr were made in patients undergoing only
coronary angiography as they were discharged earlier. Addi-
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ional measurements were performed in all cases with
eterioration of renal function after contrast exposure.
he Cr clearance (CrCl) was calculated by applying the
ockroft—Gault formula [11] to the baseline Cr concen-
ration values: CrCl = [(140-age)×weight]/[serum Cr× 72],
ith female gender adjustment (CrClfemale = CrCl× 0.85).
The contrast volume was corrected in relation to under-
ying renal function. Maximum contrast dose (MCD) was
alculated by the following formula [12]: Maximum con-
rast dose = [5mL×weight (kg)]/baseline serum Cr. Then we
alculated CM dose/MCD ratio.
We also evaluated hypertension (systolic blood pres-
ure > 140mmHg, diastolic blood pressure > 90mmHg or
eceiving antihypertensive drugs), diabetes mellitus (fast-
ng glucose level≥ 126mg/dL or random blood glucose
evel≥ 200mg/dL), current smoking habit, and hyperlipi-
emia (total cholesterol level≥ 240mg/dL, triglyceride
evel≥ 150mg/dL, or receiving hyperlipidemia medication).
nitial management
efore elective procedure, normal saline was given intra-
enously at a rate of 1mL/kg/h for 24 h. When emergency
ercutaneous coronary intervention was needed for ST ele-
ation myocardial infarction patients, they received high
ose of aspirin (300mg) and clopidogrel (300mg) and
ontinued to take low-dose aspirin (100mg) and clopido-
rel (75mg) after the procedure. In addition the patients
eceived a bolus of 5000U heparin in the emergency ward,
ollowed by continuous infusion of heparin. Target lesions
ere predilated using conventional angioplasty balloons
ollowed by stent implantation. After procedures, physio-
ogic saline was given intravenously at a rate of 1mL/kg/h
or 12 h. In patients with left ventricular dysfunction or
vert heart failure, the hydration rate was reduced to
.5mL/kg/h.
linical variables
eripheral blood samples were obtained using direct
enipuncture. The blood samples were centrifuged, and
erum was removed and stored at −70 ◦C until the assay
ould be performed. The serum levels of total cholesterol,
riglyceride, low-density lipoprotein cholesterol, and high-
ensity lipoprotein cholesterol were measured by standard
nzymatic methods. High-sensitivity C-reactive protein was
nalyzed turbidimetrically with sheep antibodies against
uman C-reactive protein. This has been validated against
he Dade—Behring method. Serum amino-terminal pro-brain
atriuretic peptide was measured using an electrochemilu-
inescence sandwich immunoassay method with an Elecsys
010 analyzer (Roche Diagnostics, Mannheim, Germany).
Left ventricular ejection fraction was usually measured in
ll patients on admission. Especially for patients with acute
yocardial infarction, the measurement was done in either
mergency room using a portable echocardiography system
Acuson Cypress, Acuson, Mountain View, CA, USA) or car-
iac catheterization laboratory using an echocardiography
ystem (Acuson Sequoia). Conventional coronary angiogra-
hy was performed using a digital ﬂat panel ﬂuoroscopy
Phillips, Eindhoven, The Netherlands) via femoral or radial
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pproaches applying nonionic isosmolar contrast material
Visipaque® 320, GE Healthcare, Cork, Ireland). A minimum
f four orthogonal views were obtained.
nd points
he primary outcome for this analysis was composite of 1-
ear adverse cardiac events. The adverse cardiac event was
eﬁned as composite of cardiac death, non-cardiac death,
nd revascularization of coronary artery.
tatistical analysis
ontinuous variables with normal distributions are pre-
ented as mean± SD and were compared with the use of
he Student’s t-test or Mann—Whitney U-test if normal-
ty assumption was violated. Categorical variables were
ompared with the use of the Chi-square test or Fisher’s
xact test, where appropriate. Multivariate logistic regres-
ion analysis was used to identify correlates of CIN. The
esponse variable was the development of CIN deﬁned as an
ncrease in Cr concentration of ≥25% or ≥0.5mg/dL. Models
ere developed with stepwise techniques and by consider-
tion of variables that were clinically relevant. Odds ratios
nd their two-sided 95% conﬁdence intervals are reported,
nd signiﬁcance was determined by the position of the 95%
onﬁdence interval. A conﬁdence interval not including 1
as considered statistically signiﬁcant. Cox proportional
azards regression was used to examine the association
C
e
c
t
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Table 1 Baseline characteristics.
C
(n
Age (years) 7
Male sex 4
Body mass index (kg/m2) 2
Hypertension 5
Diabetes mellitus 4
Hyperlipidemia 1
Smoking 2
Old myocardial infarction 4
Stable angina 8
Unstable angina 2
Acute myocardial infarction 4
Left ventricular ejection fraction (%) 5
Cardiogenic shock 4
Amount of contrast medium used (mL) 1
Maximum contrast dose (mL) 1
Contrast medium used/Maximum contrast dose ratio 0
Baseline hematocrit (%) 3
Baseline creatinine (mg/dL) 1
Creatinine clearance (mL/min) 3
Total cholesterol (mg/dL) 1
Triglyceride (mg/dL) 1
High-density lipoprotein cholesterol (mg/dL) 4
Low-density lipoprotein cholesterol (mg/dL) 9
High-sensitivity C-reactive protein (mg/dL) 2
Amino-terminal pro-brain natriuretic peptide (mg/dL) 1
Data are presented as the number (%) of patients or mean± SD. CIN, cJ.Y. Cho et al.
etween multiple variables and the long-term adverse out-
omes. Then, we calculated the hazard ratios (HRs) and
5% conﬁdence intervals (CIs) comparing event-free survival
ates between CIN and non-CIN group using the Cox propor-
ional hazard method. We determined that the proportional
azard assumption was satisﬁed by examining plots of the
og-negative-log of the within-group survivorship functions
s. log-time as well as comparing Kaplan—Meier with Cox
urvival curves. Statistical analysis was done with the Sta-
istical Package for Social Sciences software, version 15.0
SPSS Inc., Chicago, IL, USA) for Windows (Microsoft Corp.,
edmond, WA, USA).
esults
atient characteristics
aseline characteristics of the two groups are presented in
able 1. There were notable differences between patients
ith and without CIN. Patients with CIN were older
71.2± 7.9 vs. 68.9± 9.2 years, p = 0.042), more likely to be
omen (63.5% vs. 77.3%, p = 0.011), have diabetes (55.4%
s. 42.9%, p = 0.045), and have lower body mass index
22.9± 2.6 vs. 24.0± 3.3 kg/m2, p = 0.007). Patients with
IN were also more likely to have lower left ventricular
jection fraction (50.1± 12.6% vs. 57.7± 13.9%, p < 0.001),
ardiogenic shock (47.1% vs. 12.2%, p = 0.002), and a trend
oward a greater amount of CM use (138.3± 64.7 vs.
27.4± 72.8mL, p = 0.227). But, there was a signiﬁcant dif-
IN group Non-CIN group p
= 74) (n = 436)
1.2± 7.9 68.9± 9.2 0.042
7(63.5%) 337(77.3%) 0.011
2.9± 2.6 24.0± 3.3 0.007
9(79.7) 299(68.6) 0.052
1(55.4) 187(42.9) 0.045
4(18.9) 54(12.4) 0.126
7(36.5) 146(33.5) 0.614
(5.4) 39(8.9) 0.311
(10.8) 102(23.4) 0.015
1(28.4) 159(36.5) 0.178
1(55.4) 136(31.2) <0.001
0.1± 12.6 57.7± 13.9 <0.001
7.1% 12.2% 0.002
38.3± 64.7 127.4± 72.8 0.227
86.9± 42.3 219.1± 50.9 <0.001
.79± 0.45 0.63± 0.41 0.002
2.4± 5.3 36.6± 5.5 <0.001
.72± 0.49 1.52± 0.33 0.001
3.0± 10.1 42.1± 13.7 <0.001
61.3± 46.8 178.6± 44.5 0.165
12.4± 57.0 112.6± 57.0 0.988
1.5± 13.3 44.5± 13.7 0.374
9.9± 41.0 115.1± 39.2 0.168
.59± 2.02 3.61± 4.25 0.151
2843.1± 10915.7 4636.5± 7574.5 0.010
ontrast-induced nephropathy.
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Table 2 Procedural characteristics.
CIN group Non-CIN group p
(n = 74) (n = 436)
Culprit lesion
Left main 6(8.1) 16(3.7) 0.263
Left anterior descending artery 23(31.1) 182(41.7) 0.215
Left circumﬂex artery 17(23.0) 63(14.5) 0.188
Right coronary artery 29(39.2) 177(40.6) 0.827
Lesion location
Proximal 33(44.6) 220(50.5) 0.503
Middle 24(32.4) 141(32.3) 0.923
Distal 16(21.6) 73(16.7) 0.449
Multivessel disease 13(17.6) 50(11.5) 0.212
Pre-TIMI ﬂow 0.714
0 34(46.0) 213(48.9)
1 9(12.2) 72(16.5)
2 7(9.5) 8(1.8)
3 23(31.1) 143(32.8)
Lesion typea 0.530
A 34(46.0) 214(49.1)
B1 8(10.8) 53(12.2)
B2 15(20.3) 88(20.2)
C 17(23.0) 81(18.6)
Stent proﬁle
Stent diameter (mm) 3.1± 0.4 3.2± 2.0 0.761
Stent length (mm) 24.5± 7.3 25.3± 6.69 0.537
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nData are presented as the number (%) of patients or mean± SD.
a Lesion type according to American College of Cardiology/Am
thrombolysis in myocardial infarction.
ference in CM used/MCD ratio (0.79± 0.45 vs. 0.63± 0.41,
p = 0.002).
With regard to initial clinical diagnosis, more than half
of the patients with CIN were diagnosed with acute myocar-
dial infarction (55.4% vs. 31.2%, p < 0.001), while there
were fewer patients with stable angina (10.8% vs. 23.4%,
p = 0.015).
In patients with CIN, baseline Cr level was higher
(1.72± 0.49 vs. 1.52± 0.33mg/dL, p = 0.001) and accord-
ingly, CrCl was lower (33.0± 10.1 vs. 42.1± 13.7mL/min,
p < 0.001). Also, hematocrit (32.4± 5.3 vs. 36.6± 5.5%,
p < 0.001) and mean serum glucose level was lower (159± 48
vs. 196± 118mg/dL, p = 0.028). But, there were no signiﬁ-
cant differences in lipid proﬁles and inﬂammatory markers
between the two groups.
Procedural ﬁndings are summarized in Table 2. No notable
signiﬁcant procedural differences between subjects with
and without CIN were found. There were only trends
toward more multivessel diseases and complicated lesions
in patients with CIN.Predictors of CIN
Multivariate logistic regression analyses of the association
between CIN and multiple parameters are presented in
Table 3. Univariable analysis was ﬁrst conducted to iden-
t
t
w
on Heart Association; CIN, contrast-induced nephropathy; TIMI,
ify potential predictors for CIN. All variables with p < 0.2
n univariable analysis (age, sex, body mass index, diabetes
ellitus, left ventricular ejection fraction, baseline crea-
inine level, baseline hematocrit, and CM used/MCD ratio)
ere tested for multivariable analysis.
In multivariate analysis, baseline hematocrit, left ven-
ricular ejection fraction, and baseline Cr level were
redictors of CIN. The most powerful parameter to predict
IN was baseline serum Cr level (odds ratio 2.375, 95% con-
dence interval 1.273—4.428, p = 0.007), but the amount of
M failed to be an independent predictor of CIN.
linical outcomes between groups
he clinical outcomes are summarized in Table 4. There
ere more in-hospital deaths in patients with CIN. Also,
here were signiﬁcantly more hospital days for patients with
IN than for patients without CIN. Patients with CIN showed
igher mortality at 1-year follow-up. Composite adverse
utcomes in the CIN group were greater than that of the
on-CIN group (23.2% vs. 13.2%, p = 0.029), especially among
he subset of outcomes, cardiac death rate was greater in
he CIN group (14.5% vs. 2.6%, p < 0.001).
In Cox proportional hazards regression analysis, patients
ith CIN showed worse cardiac outcomes than patients with-
ut CIN in event-free survival curve adjusted for multiple
304 J.Y. Cho et al.
Table 3 Independent predictors of contrast-induced nephropathy.
Odds ratio 95% conﬁdence interval p
Baseline hematocrit 0.900 0.851—0.952 <0.001
Left ventricular ejection fraction 0.967 0.949—0.986 0.001
Baseline creatinine level 2.317 1.252—4.286 0.007
Sex 1.337 0.726—2.464 0.351
Age 1.018 0.983—1.053 0.315
Dose of contrast medium used/maximum contrast dose ratio 1.011 0.509—2.009 0.975
Body mass index 0.961 0.878—1.052 0.390
Diabetes mellitus 1.208 0.688—2.121 0.510
Table 4 Clinical outcomes between patients with and without contrast-induced nephropathy (CIN).
CIN group Non-CIN group p
(n = 74) (n = 436)
In-hospital outcomes
In-hospital death 6(8.1) 3(0.7) <0.001
Hospital day (days) 14.7± 12.1 9.1± 15.2 0.003
One-year adverse outcomes (n = 69) (n = 418)
All-cause death 11(15.9) 17(4.1) 0.001
Cardiac death 10(14.5) 11(2.6) <0.001
Non-cardiac death 1(1.4) 6(1.4) 1.000
r
2
D
T
c
w
t
h
C
t
p
S
[
w
w
i
o
d
t
t
w
w
C
M
M
m
t
w
l
C
t
C
t
r
n
p
t
N
t
i
i
o
q
r
m
c
r
o
i
m
7Revascularization 5(7.3)
Composite 16(23.2)
Data are presented as the number (%) of patients or mean± SD.
isk factors (hazard ratio 13.068, 95% conﬁdence interval
.425—70.434, p = 0.003) (Fig. 1).
iscussion
he present study indicated that even nonionic isosmolar CM
ould cause CIN to a certain degree and also the patients
ith CIN had different risk factors. The independent predic-
ors of CIN after using nonionic isosmolar CM were baseline
ematocrit, left ventricular ejection fraction, and baseline
r level. In addition, patients with CIN showed worse long-
erm cardiac outcomes than patients without CIN in Cox
roportional hazard regression analysis.
The incidence of CIN was 14.5% in the present study.
ome studies showed lower incidences of CIN than our study
7,8,13—15] and some were similar [5,16]. But, there is a
ide variation in reported rates of CIN in the real world. This
as thought to be caused by lack of a standardization, tim-
ng of Cr measurement, baseline characteristics, and type
f CM used [17].
Not all studies have demonstrated a contrast dose-
ependent risk of CIN. Lautin et al. [18] reported that
he effects of dehydration and increased volume of con-
rast medium on the incidence of CIN were not clear. Since
e examined patients undergoing coronary angiography as
ell as percutaneous coronary intervention, the amount of
M used was rather smaller compared with the data from
cCullough et al. (247.8± 113.0 vs. 129.0± 71.7 cm3) [5].
oreover, there were 136 patients out of 510 with acute
yocardial infarction, which accounted for only 31.2% of the
u
1
a
b
w38(9.1) 0.705
55(13.2) 0.029
otal population. But CIN occurred in 14.5% of total patients,
hich is exactly the same incidence as in the study by McCul-
ough et al. [5]. It might be suggested that the amount of
M is not associated with CIN by the results above. However,
he dose of CM should not be excluded as a risk factor of
IN. Rudnick et al. [19] reported that baseline serum crea-
inine, male gender, diabetes, volume of contrast agent, and
enal insufﬁciency were independently related to the risk of
ephrotoxicity. Cigarroa et al. [12] reported that diabetic
atients had a high incidence of contrast nephropathy, par-
icularly when they receive an excessive amount of contrast.
ozue et al. [20] reported that the contrast medium volume
o estimated glomerular ﬁltration rate ratio was a signiﬁcant
ndependent predictor of CIN. Nevertheless, several stud-
es reported that amount of CM had no effect on increase
f CIN any more when prophylactic therapy such as ade-
uate intravenous ﬂuid was given or the patients had better
enal function [21]. In that sense, low osmolality of contrast
edia might also be one of the prophylactic measures that
an neutralize the dose-related increase of CIN. Likewise,
isk factors and outcomes of CIN could vary according to
smolality of contrast media.
In-hospital mortality in our study was relatively low. Stud-
es so far have not shown consistent results of in-hospital
ortality of patients with CIN. McCullough et al. [5] reported
.1% in-hospital mortality in patients with acute renal fail-
re. Rihal et al. [7] reported 22% in-hospital mortality and
2.1% 1-year mortality. We had in-hospital mortality of 8.1%
nd 1 year mortality of 15.9% in patients with CIN. In terms of
aseline characteristics, the number of patients diagnosed
ith acute coronary syndrome was relatively low in this
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nephropathy. CIN, contrast-induced nephropathy; MACE, major
study. With respect to procedural characteristics, our results
have shown no signiﬁcant differences in number of patients
with multivessel disease. Some other studies have shown
that patients with CIN are more likely to have multives-
sel disease [22,23]. Since we included patients undergoing
coronary angiography as well as percutaneous coronary
intervention, the absolute incidence of multivessel disease
seemed to be lower than other studies.
The present study has several limitations. First, it was
limited because of its retrospective nature and was there-
fore subject to the limitations pertinent to this type of
clinical investigation. Not all data for variables suggested as
a risk factor of CIN so far were available. Second, this was a
single-center study and thus the result of this study should
be veriﬁed by further prospective investigation. Third,
there might be some variations of deﬁnition of CIN. The
standardization of deﬁnition of CIN is needed. Fourth, oper-
ators’ effort to reduce CIN might inﬂuence the outcomes
with the information of patients’ baseline characteris-
tics before procedures. Fifth, the relatively small sample
size might have resulted in overestimation of incidence of
adverse outcomes, limited statistical power, and selection
bias.
In conclusion, even though we used nonionic isosmolar CM
during coronary procedures, the occurrence of CIN occurred
to a certain degree. Predictors of CIN after use of nonionic
isosmolar CM during coronary angiography or percutaneous
coronary intervention were baseline Cr level, decreased
baseline hematocrit, and decreased left ventricular ejection
fraction. Patients with CIN showed worse long-term cardiac
outcomes than patients without CIN in Cox proportional haz-
ard regression analysis. These results support the idea that
we have to prevent CIN because it is associated with 1-year
mortality.cording to patient groups with or without contrast-induced
rse cardiac events.
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